© 2002

Biomedical Aspects of Drug Targeting

  • Vladimir Muzykantov
  • Vladimir Torchilin

Table of contents

  1. Front Matter
    Pages i-xvii
  2. General Principles of Drug Targeting

    1. Front Matter
      Pages 1-1
    2. Vladimir P. Torchilin
      Pages 3-26
    3. Vladimir R. Muzykantov
      Pages 27-44
  3. Cardiovascular Targeting

    1. Front Matter
      Pages 45-45
    2. Ban-An Khaw
      Pages 47-67
    3. Ban-An Khaw
      Pages 69-83
    4. Karlheinz Peter, Christoph Bode
      Pages 85-106
    5. Vladimir R. Muzykantov
      Pages 129-148
    6. Jonathan R. Lindner, Alexander L. Klibanov, Klaus Ley
      Pages 149-172
    7. Paul N. Reynolds, Sergei M. Danilov
      Pages 173-190
  4. Tumor Targeting

    1. Front Matter
      Pages 191-191
    2. Ruth Duncan
      Pages 193-209
    3. Sophia Ran, Michael Rosenblum, Philip E. Thorpe
      Pages 229-248
    4. Alan L. Epstein, Leslie A. Khawli, Peisheng Hu
      Pages 249-274
    5. Susanna M. Rybak, Michaela Arndt, Juergen Krauss, Dianne L. Newton, Bang K. Vu, Zhongyu Zhu
      Pages 275-290
    6. Victor S. Goldmacher, Walter A. Blättler, John M. Lambert, Ravi V. J. Chari
      Pages 291-309
  5. Targeting to the Brain

    1. Front Matter
      Pages 311-311

About this book


Drugs usually have no natural affinity for the cells, tissues and organs where therapeutic effects are needed, which frequently results in low efficiency and unwanted side effects. This concern is even more profound when using highly potent and cytotoxic anticancer drugs or specific agents, such as enzymes and genetic materials, since their effective and safe action requires precise cellular or even sub-cellular addressing in the target organ. To meet safety, efficiency and specificity requirements, drugs somehow must be targeted to the sites of their expected therapeutic action. The idea of the "magic bullet," or drug targeting, proposed by Erlich a century ago, generates great and continuously growing interest in biomedical, industrial and financial circles. This book is focused on the strategies designed to target therapeutic or diagnostic agents to the disease sites. In an attempt to include in this volume the set of chapters reflecting both traditional and emerging areas of drug targeting, we have contacted many leading scientists in the field asking for their contributions. Their responses were most favorable and encouraging. As a result, we have succeeded in assembling a series of outstanding contributions reflecting practically all the key areas of drug targeting. The final structure of this book is as follows.


Epoxidharze Retention Tumor apoptosis endothelium imaging polymer tissue

Editors and affiliations

  • Vladimir Muzykantov
    • 1
  • Vladimir Torchilin
    • 2
  1. 1.School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.School of PharmacyNortheastern UniversityBostonUSA

Bibliographic information